Among them, inhibitors of programmed death receptor-1 (PD-1) and programmed death ligand-1 (PD-L1) exhibit strong anti-tumor activity and are safe for the management of HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.